Pharmacotherapeutic strategies for atrial fibrillation in pregnancy

References

• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Choi HS, Han SS, Choi HA, et al. Dyspnea and palpitation during pregnancy. Korean J Intern Med. 2001;16(4):247–249.
   PubMedGoogle Scholar
• Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol. 1997;79(8):1061–1064.
   PubMed Web of Science ®Google Scholar
• Lee MS, Chen W, Zhang Z, et al. Atrial fibrillation and atrial flutter in pregnant women-A population-based study. J Am Heart Assoc. 2016;5(4):e003182.
   PubMed Web of Science ®Google Scholar
• Vaidya VR, Arora S, Patel N, et al. Burden of arrhythmia in pregnancy. Circulation. 2017;135(6):619–621.
   PubMed Web of Science ®Google Scholar
• Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol. 2007;49(24):2303–2311.
   PubMed Web of Science ®Google Scholar
• Opotowsky AR, Siddiqi OK, D’Souza B, et al. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart. 2012;98(2):145–151.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–3241.
   PubMed Web of Science ®Google Scholar
• Martin JA, Hamilton BE, Osterman MJK, et al. Births: final Data for 2016. Natl Vital Stat Rep. 2018;67(1):1–55.
   Google Scholar
• Mathews TJ, Hamilton BE. Mean age of mother, 1970-2000. Natl Vital Stat Rep. 2002;51(1):1–13.
   PubMedGoogle Scholar
• Eurostat. Fertility statistics [Internet]. March 2019 [cited 2019 Apr 13]. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php/Fertility_statistics#The_birth_rate_in_the_EU_decreased_at_a_slower_pace_between_2000_and_2017_than_before
   Google Scholar
• OECD - Social Policy Division - Directorate of Employment, Labour and Social Affairs. SF2.3: Age of mothers at childbirth and age-specific fertility [Internet]. 10 July 2018 [cited 2019 Apr 13]. Available from: https://www.oecd.org/els/soc/SF_2_3_Age_mothers_childbirth.pdf
   Google Scholar
• European Society of G, Association for European Paediatric C, German Society for Gender M, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147–3197.
   PubMed Web of Science ®Google Scholar
• Cacciotti L, Passaseo I. Management of atrial fibrillation in pregnancy. J Atr Fibrillation. 2010;3(3):295.
   PubMedGoogle Scholar
• White S, Welch J, Brown LH. The unexpected pitter patter: new-onset atrial fibrillation in pregnancy. Case Rep Emerg Med. 2015;2015:318645.
   PubMedGoogle Scholar
• Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol. 1993;72(11):838–840.
   PubMed Web of Science ®Google Scholar
• Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476–484.
   PubMed Web of Science ®Google Scholar
• Pallisgaard JL, Schjerning AM, Lindhardt TB, et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621–627.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–162.
   PubMed Web of Science ®Google Scholar
• Sauve N, Rey E, Cumyn A. Groupe d’Etude en Medecine Obstetricale du Q. Atrial fibrillation in a structurally normal heart during pregnancy: a review of cases from a registry and from the literature. J Obstet Gynaecol Can. 2017;39(1):18–24.
   PubMed Web of Science ®Google Scholar
• Wong JA, Rexrode KM, Sandhu RK, et al. Number of pregnancies and atrial fibrillation risk: the women’s health study. Circulation. 2017;135(6):622–624.
   PubMed Web of Science ®Google Scholar
• Salam AM, Ertekin E, van Hagen IM, et al. Atrial fibrillation or flutter during pregnancy in patients with structural heart disease: data from the ROPAC (Registry on pregnancy and cardiac disease). JACC Clin Electrophysiol. 2015;1(4):284–292.
   PubMedGoogle Scholar
• Dzeshka MS, Shahid F, Shantsila A, et al. Hypertension and atrial fibrillation: an intimate association of epidemiology, pathophysiology, and outcomes. Am J Hypertens. 2017;30(8):733–755.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Shantsila A, Shantsila E, et al. Atrial fibrillation and hypertension. Hypertension. 2017;70(5):854–861.
   PubMed Web of Science ®Google Scholar
• Rani U, Praveen Kumar KS, Munisamaiah M, et al. Atrial fibrillation associated genetic variation near PITX2 gene increases the risk of preeclampsia. Pregnancy Hypertens. 2018;13:214–217.
   PubMed Web of Science ®Google Scholar
• Scantlebury DC, Kattah AG, Weissgerber TL, et al. Impact of a history of hypertension in pregnancy on later diagnosis of atrial fibrillation. J Am Heart Assoc. 2018;7(10). pii: e007584.
   PubMed Web of Science ®Google Scholar
• Sengheiser CJ, Channer KC. Recurrent atrial flutter and fibrillation in pregnancy.BMJ Case Rep. 2011;2011. pii: bcr1220103589.
   PubMedGoogle Scholar
• Ntusi NB, Badri M, Gumedze F, et al. Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. PLoS One. 2015;10(8):e0133466.
   PubMed Web of Science ®Google Scholar
• Goland S, van Hagen IM, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J. 2017;38(35):2683–2690.
   PubMed Web of Science ®Google Scholar
• Carson MP, Fisher AJ, Scorza WE. Atrial fibrillation in pregnancy associated with oral terbutaline. Obstet Gynecol. 2002;100(5 Pt 2):1096–1097.
   PubMed Web of Science ®Google Scholar
• Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. Bjog. 2006;113(7):844–845.
   PubMed Web of Science ®Google Scholar
• Fu Q, Levine BD. Autonomic circulatory control during pregnancy in humans. Semin Reprod Med. 2009;27(4):330–337.
   PubMed Web of Science ®Google Scholar
• Chung E, Leinwand LA. Pregnancy as a cardiac stress model. Cardiovasc Res. 2014;101(4):561–570.
   PubMed Web of Science ®Google Scholar
• Yosefy C, Shenhav S, Feldman V, et al. Left atrial function during pregnancy: a three-dimensional echocardiographic study. Echocardiography. 2012;29(9):1096–1101.
   PubMed Web of Science ®Google Scholar
• Li J, Umar S, Amjedi M, et al. New frontiers in heart hypertrophy during pregnancy. Am J Cardiovasc Dis. 2012;2(3):192–207.
   PubMedGoogle Scholar
• Bailey MS, Curtis AB. The effects of hormones on arrhythmias in women. Curr Womens Health Rep. 2002;2(2):83–88.
   PubMedGoogle Scholar
• Rosano GM, Leonardo F, Sarrel PM, et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347(9004):786–788.
   PubMed Web of Science ®Google Scholar
• Anugu VR, Nalluri N, Asti D, et al. New-onset lone atrial fibrillation in pregnancy. Ther Adv Cardiovasc Dis. 2016;10(4):274–276.
   PubMedGoogle Scholar
• Linz D, Hohl M, Vollmar J, et al. Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction. Europace. 2017;19(1):16–20.
   PubMed Web of Science ®Google Scholar
• Body C, Christie JA. Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. Gastroenterol Clin North Am. 2016;45(2):267–283.
   PubMed Web of Science ®Google Scholar
• DiCarlo-Meacham A, Dahlke J. Atrial fibrillation in pregnancy. Obstet Gynecol. 2011;117(2 Pt 2):489–492.
   PubMed Web of Science ®Google Scholar
• Wang YC, Chen CH, Su HY, et al. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):268–269.
   PubMed Web of Science ®Google Scholar
• Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG. 2002;109(12):1406–1407.
   PubMed Web of Science ®Google Scholar
• Tromp CH, Nanne AC, Pernet PJ, et al. Electrical cardioversion during pregnancy: safe or not? Neth Heart J. 2011;19(3):134–136.
   PubMed Web of Science ®Google Scholar
• Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995;130(4):871–876.
   PubMed Web of Science ®Google Scholar
• Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017;19(3):465–511.
   PubMed Web of Science ®Google Scholar
• Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol. 2001;38(5):1498–1504.
   PubMed Web of Science ®Google Scholar
• Kockova R, Kocka V, Kiernan T, et al. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol. 2007;18(5):545–547.
   PubMed Web of Science ®Google Scholar
• Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997;96(12):4298–4306.
   PubMed Web of Science ®Google Scholar
• Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31(6):1414–1419.
   PubMed Web of Science ®Google Scholar
• Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 1998;79(6):568–575.
   PubMed Web of Science ®Google Scholar
• Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011;24(1):86–92.
   PubMed Web of Science ®Google Scholar
• Marks TA, Terry RD. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology. 1996;54(3):157–164.
   PubMedGoogle Scholar
• Lewis G, Currie P. Atrial fibrillation during pregnancy: cardioversion with flecainide. Br J Hosp Med (Lond). 2015;76(12):720–721.
   PubMed Web of Science ®Google Scholar
• Strizek B, Berg C, Gottschalk I, et al. High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia. Heart Rhythm. 2016;13(6):1283–1288.
   PubMed Web of Science ®Google Scholar
• Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation. 2003;108(15):1871–1909.
   PubMed Web of Science ®Google Scholar
• Halpern DG, Weinberg CR, Pinnelas R, et al. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(4):457–476.
   PubMed Web of Science ®Google Scholar
• Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(12). pii: e007164.
   PubMed Web of Science ®Google Scholar
• Hill LM, Malkasian GD Jr. The use of quinidine sulfate throughout pregnancy. Obstet Gynecol. 1979;54(3):366–368.
   PubMed Web of Science ®Google Scholar
• Widerhorn J, Rubin JN, Frishman WH, et al. Cardiovascular drugs in pregnancy. Cardiol Clin. 1987;5(4):651–674.
   PubMedGoogle Scholar
• Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009;25(7):421–424.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001;24(2):116–130.
   PubMed Web of Science ®Google Scholar
• Lomenick JP, Jackson WA, Backeljauw PF. Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol. 2004;24(6):397–399.
   PubMedGoogle Scholar
• Skold AC, Danielsson BR. Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol. Toxicol Pharmacol. 2001;88(1):34–39.
   PubMedGoogle Scholar
• Babin JP, Carre M, Martin C. [Possible embryofetopathy caused by beta-blocker (sotalol) taken throughout the pregnancy]. Pediatrie. 1985;40(2):129–136.
   PubMedGoogle Scholar
• Oudijk MA, Ruskamp JM, Ververs FF, et al. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol. 2003;42(4):765–770.
   PubMed Web of Science ®Google Scholar
• Sherman JLLR. Transplacental neonatal digitalis intoxication. Am J Cardiol. 1960;6:834–837.
   Web of Science ®Google Scholar
• Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol. 2002;118(1):132–140.
   PubMed Web of Science ®Google Scholar
• Schlebusch H, von Mende S, Grunn U. et al. Determination of digoxin in the blood of pregnant women, fetuses and neonates before and during anti-arrhythmic therapy, using four immunochemical methods. Eur J Clin Chem Clin Biochem. 1991;29(1):57–66.
   PubMedGoogle Scholar
• Yalaz M, Levent E, Olukman M, et al. Role of digoxin-like immunoreactive substance in the pathogenesis of transient tachypnea of newborn. Biomed Res Int. 2013;2013:704763.
   PubMedGoogle Scholar
• Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension. 2013;62(2):375–381.
   PubMed Web of Science ®Google Scholar
• Bergman JEH, Lutke LR, Gans ROB, et al. Beta-blocker use in pregnancy and risk of specific congenital anomalies: a european case-malformed control study. Drug Saf. 2018;41(4):415–427.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Patorno E, Desai RJ, et al. Late Pregnancy beta Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics. 2016;138:3.
   Web of Science ®Google Scholar
• Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4). pii: e001185.
   PubMed Web of Science ®Google Scholar
• Davis RL, Eastman D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20(2):138–145.
   PubMed Web of Science ®Google Scholar
• Duan L, Ng A, Chen W, et al. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich). 2018;20(11):1603–1609.
   PubMed Web of Science ®Google Scholar
• Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2000;4:CD002863.
   Google Scholar
• Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541–547.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tanaka H, Kamiya C, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016;80(10):2221–2226.
   PubMed Web of Science ®Google Scholar
• Eliahou HE, Silverberg DS, Reisin E, et al. Propranolol for the treatment of hypertension in pregnancy. Br J Obstet Gynaecol. 1978;85(6):431–436.
   PubMedGoogle Scholar
• Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound. 1985;13(4):265–273.
   PubMed Web of Science ®Google Scholar
• Ariyuki F. Effects of diltiazem hydrochloride on embryonic development: species differences in the susceptibility and stage specificity in mice, rats, and rabbits. Okajimas Folia Anat Jpn. 1975;52(2–3):103–117.
   PubMedGoogle Scholar
• Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387–454.
   PubMed Web of Science ®Google Scholar
• Driver K, Chisholm CA, Darby AE, et al. Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol. 2015;26(6):698–702.
   PubMed Web of Science ®Google Scholar
• Sedlak T, Shufelt C, Iribarren C, et al. Sex hormones and the QT interval: a review. J Womens Health (Larchmt). 2012;21(9):933–941.
   PubMed Web of Science ®Google Scholar
• Zamani M, Esmailian M, Yoosefian Z. QT interval in pregnant and non-pregnant women. Emerg (Tehran). 2014;2(1):22–25.
   PubMedGoogle Scholar
• Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Jama. 1993;270(21):2590–2597.
   PubMed Web of Science ®Google Scholar
• van Hagen IM, Roos-Hesselink JW, Ruys TP, et al. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015;132(2):132–142.
   PubMed Web of Science ®Google Scholar
• Lawley CM, Lain SJ, Algert CS, et al. Prosthetic heart valves in pregnancy, outcomes for women and their babies: a systematic review and meta-analysis. Bjog. 2015;122(11):1446–1455.
   PubMed Web of Science ®Google Scholar
• Soma-Pillay P, Nene Z, Mathivha TM, et al. The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstet Med. 2011;4(1):24–27.
   PubMedGoogle Scholar
• Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191–196.
   PubMedGoogle Scholar
• D’Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J. 2017;38(19):1509–1516.
   PubMed Web of Science ®Google Scholar
• Sillesen M, Hjortdal V, Vejlstrup N, et al. Pregnancy with prosthetic heart valves - 30 years’ nationwide experience in Denmark. Eur J Cardiothorac Surg. 2011;40(2):448–454.
   PubMed Web of Science ®Google Scholar
• van Driel D, Wesseling J, Sauer PJ, et al. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002;66(3):127–140.
   PubMedGoogle Scholar
• Wesseling J, Van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost. 2001;85(4):609–613.
   PubMed Web of Science ®Google Scholar
• Xu Z, Fan J, Luo X, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis. Can J Cardiol. 2016;32(10):1248e1- e9.
   Web of Science ®Google Scholar
• Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33(6):1637–1641.
   PubMed Web of Science ®Google Scholar
• Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2014;18(6):797–806.
   PubMed Web of Science ®Google Scholar
• Casele HL. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Clin Obstet Gynecol. 2006;49(4):895–905.
   PubMed Web of Science ®Google Scholar
• Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–407.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Beck E, Meixner K, et al. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016;105(2):117–126.
   PubMed Web of Science ®Google Scholar
• Cohen H, Arachchillage DR, Middeldorp S, et al. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(8):1673–1676.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost. 2016;116(4):651–658.
   PubMed Web of Science ®Google Scholar